Edge Therapeutics, Inc. (EDGE) Scheduled to Post Quarterly Earnings on Monday
Edge Therapeutics, Inc. (NASDAQ:EDGE) is scheduled to be announcing its earnings results on Monday, October 30th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
Edge Therapeutics (NASDAQ:EDGE) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.44). On average, analysts expect Edge Therapeutics to post $-1.87 EPS for the current fiscal year and $-1.74 EPS for the next fiscal year.
Edge Therapeutics, Inc. (NASDAQ EDGE) opened at 10.46 on Monday. The stock’s market capitalization is $322.70 million. The company’s 50-day moving average is $10.25 and its 200 day moving average is $10.17. Edge Therapeutics, Inc. has a 1-year low of $7.30 and a 1-year high of $13.50.
Several brokerages recently commented on EDGE. BidaskClub lowered shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th.
COPYRIGHT VIOLATION NOTICE: “Edge Therapeutics, Inc. (EDGE) Scheduled to Post Quarterly Earnings on Monday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/23/edge-therapeutics-inc-edge-scheduled-to-post-quarterly-earnings-on-monday.html.
In other news, insider Albert N. Marchio II sold 2,500 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $10.42, for a total transaction of $26,050.00. Following the completion of the sale, the insider now owns 3,361 shares of the company’s stock, valued at $35,021.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian A. Leuthner sold 7,500 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $10.21, for a total transaction of $76,575.00. Following the sale, the insider now directly owns 117,736 shares of the company’s stock, valued at approximately $1,202,084.56. The disclosure for this sale can be found here. In the last three months, insiders sold 36,000 shares of company stock valued at $379,315. 36.19% of the stock is owned by insiders.
A hedge fund recently raised its stake in Edge Therapeutics stock. The Manufacturers Life Insurance Company raised its holdings in shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) by 26.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,114 shares of the biotechnology company’s stock after buying an additional 3,764 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.06% of Edge Therapeutics worth $186,000 as of its most recent SEC filing. Institutional investors own 49.38% of the company’s stock.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.